Literature DB >> 18486038

Capreomycin.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18486038     DOI： 10.1016/S1472-9792(08)70004-0

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN： 1472-9792            Impact factor:   3.131


× No keyword cloud information.
  6 in total

1.  Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables.

Authors:  Priti Kambli; Kanchan Ajbani; Chaitali Nikam; Meeta Sadani; Anjali Shetty; Zarir Udwadia; Sophia B Georghiou; Timothy C Rodwell; Antonino Catanzaro; Camilla Rodrigues
Journal:  Int J Mycobacteriol       Date:  2015-10-01

Review 2.  Nervous system effects of antituberculosis therapy.

Authors:  Joseph S Kass; Wayne X Shandera
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

3.  Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs.

Authors:  L Garcia-Contreras; Pavan Muttil; John K Fallon; Mohan Kabadi; Robert Gerety; Anthony J Hickey
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

Review 4.  Safety and tolerability profile of second-line anti-tuberculosis medications.

Authors:  Geetha Ramachandran; Soumya Swaminathan
Journal:  Drug Saf       Date:  2015-03       Impact factor: 5.606

5.  Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis.

Authors:  Ashwin S Dharmadhikari; Mohan Kabadi; Bob Gerety; Anthony J Hickey; P Bernard Fourie; Edward Nardell
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

6.  High frequency of resistance, lack of clinical benefit, and poor outcomes in capreomycin treated South African patients with extensively drug-resistant tuberculosis.

Authors:  Elize Pietersen; Jonny Peter; Elizabeth Streicher; Frik Sirgel; Neesha Rockwood; Barbara Mastrapa; Julian Te Riele; Malika Davids; Paul van Helden; Robin Warren; Keertan Dheda
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.